Blueberries: from superfood to a potential PTSD treatment
In a series of studies conducted on rats, researchers from Louisiana State University's School of Veterinary Medicine have found…
By
Taylor Heyman
All Articles
Benign by design: the long road to biodegradable drugs
The technology exists to create biodegradable drugs, but is the pharmaceutical industry ready for a new way of thinking?…
By
A new pharmaceutical hope for heroin addiction?
For a small group of chronic heroin users, conventional treatments do not work and there is a case to…
By
Durbin CEO Leslie Morgan talks saving lives through the supply chain
Industry veteran Leslie Morgan, CEO of medical supply company Durbin, has more experience of the pharmaceutical supply chain than…
By
Olive leaf extract: on trial
The Mediterranean diet – featuring a high consumption of olive oil – has long been associated with longevity and…
By
Russia: a bright future for clinical trials?
An impressive 70% of new drugs registered in Europe in 2015 were tested in phase II-III clinical trials in…
By
Pregnancy and childbirth: where are the new drugs?
Pregnancy and childbirth still pose significant health risks for women, and while new drug approvals are thin on the…
By
Sick, dying and on a placebo: could we do away with it altogether?
Fear about receiving the placebo is one of the biggest barriers to clinical trial recruitment but with new trial…
By